NEW YORK, August 18, 2026, 13:55 EDT — U.S. cash markets remained open.
- UiPath shares were around $15.70, approximately 14% higher than the consensus analyst target.
- The stock rose about 41% over the past year.
- Fiscal Q2 earnings are scheduled for release after market close on September 3.
UiPath Inc. NYSE:PATH declined 1.8%, ending Tuesday near $15.70. The shares are still trading 13.8% over the average Wall Street target of $13.80, leaving limited buffer for any standard quarterly performance.
The automation software company’s shares are up roughly 41% over the past year. They are currently trading 30% above their 50-day moving average. Investors have bid up the stock at a pace that has outstripped analysts’ forecast upgrades.
| Trading measure | August 18 reading | Investor context |
|---|---|---|
| Share price | $15.70 | Falls 1.8% during session |
| Day range | $15.00–$15.95 | 6.3% intraday spread |
| Volume by 13:55 EDT | 53.7 million | At 82% of past three-month average |
| 50-day average | $12.08 | Shares trading 30.0% above |
| 200-day average | $12.73 | Stock currently 23.4% higher |
| 52-week range | $9.20–$19.84 | Currently 20.9% under its high |
UiPath featured as one of Yahoo Finance’s top-traded U.S. stocks. By 13:55 EDT, trading volume had reached around 53.7 million shares, a substantial figure, though not yet matching typical full-session levels.
A challenging test is on the horizon. UiPath is set to release its fiscal second-quarter results following the market close on September 3. The company’s management has arranged their conference call for 17:00 EDT.
| Operating measure | Fiscal Q1 2027 | Current guidance | Key comparison |
|---|---|---|---|
| Revenue | $418 million | Q2: $395–$400 million | Midpoint sequential decline of 4.9% |
| ARR | $1.901 billion | Q2: $1.929–$1.934 billion | Midpoint sequential increase of 1.6% |
| ARR growth | 12% year over year | FY-end: $2.058–$2.063 billion | Ongoing growth required |
| GAAP operating income | $28 million | Not guided | First fiscal Q1 in the black |
| Non-GAAP operating income | $92 million | Q2: about $75 million | Guidance represents 18.5% drop from Q1 |
| Adjusted free cash flow | $130 million | Not guided quarterly | 31% of Q1 revenue |
The outlook presents a tough challenge. Revenue may decline seasonally from the first quarter. However, UiPath now faces expectations to uphold margins and deliver increased subscription growth.
Revenue for the first quarter climbed 17%, while ARR grew by 12%. Dollar-based net retention was at 109%. CEO Daniel Dines stated agentic products were “moving from pilot to production.” UiPath fiscal Q1 filing
That statement now requires numerical backing. The Q2 ARR midpoint suggests sequential additions of just $30.5 million. A strong outperformance would bolster the case for a rerating. Results close to guidance may validate analysts’ cautious stance.
| Analyst measure | Count or target | Return from $15.70 |
|---|---|---|
| Buy | 2 analysts | — |
| Hold | 14 analysts | — |
| Sell | 1 analyst | — |
| Low target | $12.00 | -23.6% |
| Average target | $13.80 | -12.1% |
| High target | $18.00 | +14.6% |
Analysts remain conservative in their outlook. Out of 17 analysts, 14 have a hold rating on UiPath. The top price target of $18 provides less potential upside than the difference between the average target and current price.
The company’s balance sheet provides a safeguard. As of April, UiPath possessed $1.42 billion in cash and marketable securities, representing roughly 17% of its $8.1 billion market capitalization on Tuesday.
Risks: The launch of new AI agents by major software providers may create downward pressure on UiPath’s pricing and contract renewals. Additionally, UiPath depends on non-GAAP projections that omit variable share-based compensation and other expenses. Any softness in ARR figures could swiftly undo recent gains in valuation.
For investors, September 3 is more significant for gauging whether agentic automation can accelerate ARR beyond 12% than for another earnings outperformance. Expectations of substantial advancement are already reflected in the share price.
Related articles: NYSE:PATH
